Review on lipegfilgrastim

Review on lipegfilgrastim

Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we...

Full description

Saved in:
Bibliographic Details
Main Authors: Gasparic M, Leyman S
Format: article
Language:EN
Published: Dove Medical Press 2015
Subjects:
Medicine (General)
R5-920
Online Access:https://doaj.org/article/71f97796db5a4d8f91a8d2a32e5ba85e
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:doaj.org-article:71f97796db5a4d8f91a8d2a32e5ba85e
record_format dspace
spelling oai:doaj.org-article:71f97796db5a4d8f91a8d2a32e5ba85e2021-12-02T00:59:55ZReview on lipegfilgrastim1178-2013https://doaj.org/article/71f97796db5a4d8f91a8d2a32e5ba85e2015-11-01T00:00:00Zhttps://www.dovepress.com/review-on-lipegfilgrastim-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we would therefore like to clarify what lipegfilgrastim actually is.The description of lipegfilgrastim used in the original article was a “long-acting biosimilar filgrastim”.1 This description was subsequently amended in the corrigendum to “lipegfilgrastim has an active substance that is similar to filgrastim, with similar pharmacokinetics, receptor binding affinity, safety and efficacy as pegfilgrastim”.2  Read the CorrigendumGasparic MLeyman SDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2015, Iss default, Pp 6863-6864 (2015)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Gasparic M
Leyman S
Review on lipegfilgrastim
description Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we would therefore like to clarify what lipegfilgrastim actually is.The description of lipegfilgrastim used in the original article was a “long-acting biosimilar filgrastim”.1 This description was subsequently amended in the corrigendum to “lipegfilgrastim has an active substance that is similar to filgrastim, with similar pharmacokinetics, receptor binding affinity, safety and efficacy as pegfilgrastim”.2  Read the Corrigendum
format article
author Gasparic M
Leyman S
author_facet Gasparic M
Leyman S
author_sort Gasparic M
title Review on lipegfilgrastim
title_short Review on lipegfilgrastim
title_full Review on lipegfilgrastim
title_fullStr Review on lipegfilgrastim
title_full_unstemmed Review on lipegfilgrastim
title_sort review on lipegfilgrastim
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/71f97796db5a4d8f91a8d2a32e5ba85e
work_keys_str_mv AT gasparicm reviewonlipegfilgrastim
AT leymans reviewonlipegfilgrastim
_version_ 1718403392048463872

Similar Items